Drugs / TTK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00995358 | Nov 2008 → Oct 2010 | esophageal squamous cell carcinoma | University of Yamanashi | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTK | “Since a phase I clinical trial using three HLA-A24-binding peptides from TTK protein kinase (TTK), lymphocyte antigen-6 complex locus K (LY6K), and insulin-like growth...” PMID 22776426 ↗ Jul 2012 |
| Target | TTK | “three HLA-A24-binding peptides from TTK protein kinase (TTK)” PMID 22776426 ↗ Jul 2012 |